|Bid||97.00 x 800|
|Ask||100.00 x 21500|
|Day's Range||96.96 - 98.00|
|52 Week Range||76.41 - 98.00|
|PE Ratio (TTM)||42.19|
|Earnings Date||Nov 20, 2018|
|Forward Dividend & Yield||2.00 (2.06%)|
|1y Target Est||102.60|
September 22, 2018 - Investigators today unveiled new clinical data from the physician-initiated BIONYX study, representing the first all-comers analysis in nearly 2,500 patients comparing the safety and efficacy of the durable polymer Resolute Onyx(TM) drug-eluting stent (DP-DES) from Medtronic plc (MDT) to the Orsiro biodegradable polymer stent (BP-DES). At one year, the study showed patients with coronary artery disease who were treated with Orsiro BP-DES received no clinical advantage compared to patients treated with the Resolute Onyx DP-DES, and Orsiro BP-DES demonstrated a higher rate of stent thrombosis.1 Published simultaneously in The Lancet, the results were presented today during a Late-Breaking Clinical Trial session at the 30th Transcatheter Cardiovascular Therapeutics conference (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.
Investors who want to cash in on Medtronic plc’s (NYSE:MDT) upcoming dividend of US$0.50 per share have only 4 days left to buy the shares before its ex-dividend date, 27Read More...
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Notice how FedEx has come right back even though it was supposed to be such a disappointing quarter. ActionAlerts, my charitable trust, has others, but they may be too so-called go-go for you.
On a mixed day for the major benchmarks, Medtronic announced plans to buy Mazor Robotics, and Micron Technology beat expectations for its latest quarter.
The deal will have Medtronic acquiring Mazor Robotics (OTCMKTS:MZRTF) for $1.64 billion. It will be doing this by purchasing all outstanding shares of Mazor Robotics stock for $58.50 per American Depository Share, or $29.25 per ordinary share. Medtronic says that it will be using cash to fund its acquisition of Mazor Robotics stock.
NEW YORK, Sept. 21, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All Persons or Entities who purchased Mazor Robotics, Inc. stock prior to September 20, 2018. You are hereby ...
The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.
Here are some of the companies with shares expected to trade actively in Friday’s session. Check back closer to the market open for an updated list. Micron Technology Inc.—Down 2.7%: The memory chip maker issued a disappointing forecast with its fiscal fourth-quarter report, expecting revenue for the quarter ending in November to grow by its slowest rate in two years.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 20.) Abbott Laboratories (NYSE: ABT ) Acceleron ...
On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15. The dividend of $0.28 per share will be paid to shareholders of record as of the close of business on October 15. The company’s annual dividend in 2017 was $1.06, while its indicated annual dividend for 2018 is $1.12 per share. Last year, it paid a quarterly dividend of $0.265 to its shareholders, so its new quarterly dividend represents an increase of ~5.7%.
Sept 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Friday: ** Adobe Systems Inc has agreed to buy Marketo Inc for $4.75 billion from private equity ...
Medtronic agreed to pay $58.50 per American Depository Share or $29.25 (104.80 shekels) per ordinary share in cash and the boards of both companies unanimously approved the deal. Medtronic, which held a stake of about 11 percent prior to the deal, said the deal was expected to be modestly dilutive to its fiscal 2019 adjusted earnings per share.
Medical equipment company Medtronic Plc will acquire Israel-based Mazor Robotics for about $1.64 billion in an all-cash deal, or $1.34 billion net of Medtronic's existing stake in Mazor, the companies said on Thursday. Medtronic agreed to pay $58.50 per American Depository Share or $29.25 (104.80 shekels) per ordinary share in cash and the boards of both companies unanimously approved the deal. Medtronic, which held a stake of about 11 percent prior to the deal, said the deal was expected to be modestly dilutive to its fiscal 2019 adjusted earnings per share.
Under the agreement, Dublin-based Medtronic will acquire all outstanding ordinary shares of Israel-based Mazor Robotics for $58.50 per American Depository Share, or $29.25 per ordinary share, in cash. The deal is expected to close during Medtronic’s third fiscal quarter, ending Jan. 25, the companies said Thursday. ADRs of Mazor closed Thursday at $52.75 and its ordinary shares closed at $26.25.
DUBLIN and CAESAREA, Israel, Sept. 20, 2018 /PRNewswire/ -- Medtronic plc (MDT), a global leader in medical technology, and Mazor Robotics (NASDAQ: MZOR, TASE: MZOR.TA), a pioneer in the field of robotic guidance systems, today announced the companies have entered into a definitive merger agreement under which Medtronic will acquire all outstanding ordinary shares of Mazor for $58.50 per American Depository Share, or $29.25 (104.80 ILS) per ordinary share, in cash, for a total of approximately $1.64 billion, or $1.34 billion net of Medtronic's existing stake in Mazor and cash acquired. Medtronic's acquisition of Mazor strengthens Medtronic's position as a global leader in enabling technologies for spine surgery, and drives Mazor Robotics' vision to bring its core technology to the forefront of the global market.
Medtronic Plc, agreed to buy Mazor Robotics Ltd., a maker of robotic guidance systems, in a $1.64 billion cash deal to strengthen its position in technology for spine surgery. Medtronic agreed to pay $58.50 per American depositary share for the stock in Mazor that it doesn’t already own, the companies said in a joint statement Thursday. Medtronic previously held an 11 percent stake in the Israel-based company, according to Bloomberg data.
Medtronic PLC said late Thursday that it plans to buy the Israel-based Mazor Robotics Ltd. for $1.64 billion in cash. Mazor stock is up 7.5% and Medtronic fell less than 0.1% after hours. The S&P 500 index closed up 0.8%. Medtronic, a medical technology maker, said it would pay $58.50 for each American Depository Share of Mazor, which makes robotic guidance systems that are applied to medical tech. "The Mazor team and product portfolio's full integration into Medtronic will maximize our impact globally through Medtronic's channels, advance our systems' leadership position in the marketplace, and drive the realization of our vision to heal through innovation," said Mazor CEO Ori Hadomi. The acquisition is expected to close during Medtronic's third fiscal quarter, which ends Jan. 25, 2019.
September 20, 2018 - Medtronic plc (MDT), a global leader in medical technology, and Mazor Robotics (NASDAQ:MZOR, TASE:MZOR.TZ), a pioneer in the field of robotic guidance systems, today announced the companies have entered into a definitive merger agreement under which Medtronic will acquire all outstanding ordinary shares of Mazor for $58.50 per American Depository Share, or $29.25 (104.80 ILS) per ordinary share, in cash, for a total of approximately $1.64 billion, or $1.34 billion net of Medtronic`s existing stake in Mazor and cash acquired. The boards of directors of both companies have unanimously approved the transaction. Medtronic`s acquisition of Mazor strengthens Medtronic`s position as a global leader in enabling technologies for spine surgery, and drives Mazor Robotics` vision to bring its core technology to the forefront of the global market.
The following stock has been highlighted by VantagePoint Software , an artificial intelligence platform that provides market forecasts 1-3 days in advance. For a free demo click here. Shares of Medtronic ...
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date). In the same period, the S&P 500 has risen ~8%. Abbott Laboratories has clearly surpassed the market’s returns so far in 2018.
Sensible investors years ago could have chosen market leaders like Polaroid, General Motors (NYSE:GM), Sears (NASDAQ:SHLD), and myriad other ‘safe’, seemingly dominant stocks that would go on to stumble badly — or even go bankrupt. It’s far from guaranteed, however, that even torrid growth will produce much in the way of long-term returns relative to the stocks’ current prices.